• 1. Excitable dynamics in the bromate–sulfite–ferrocyanide reaction
  J. Zagora,M. Vosla?,L. Schreiberová,I. Schreiber Phys. Chem. Chem. Phys., 2002,4, 1284-1291
• 2. Exchangeability of amino acid residues with similar physicochemical properties in coiled-coil interactions?
  Guiying Zhang,Maosheng Cheng,Yanni Li,Keliang Liu,Lifeng Cai Chem. Commun., 2013,49, 11086-11088
• 3. Fe(ii)-Assisted one-pot synthesis of ultra-small core–shell Au–Pt nanoparticles as superior catalysts towards the HER and ORR?
  Yi Cao,Yujiao Xiahou,Lixiang Xing,Xiang Zhang,Hong Li,ChenShou Wu,Haibing Xia Nanoscale, 2020,12, 20456-20466
• 4. Enantio- & chemo-selective preparation of enantiomerically enriched aliphatic nitro alcohols using Candida parapsilosis ATCC 7330
  Sowmyalakshmi Venkataraman RSC Adv., 2015,5, 73807-73813
• 5. Evolved polymerases facilitate selection of fully 2′-OMe-modified aptamers?
  Zhixia Liu,Tingjian Chen,Floyd E. Romesberg Chem. Sci., 2017,8, 8179-8182

• Solvents and Organic Chemicals Organic Compounds Lipids and lipid-like molecules Glycerolipids Alkyldiacylglycerols
• Solvents and Organic Chemicals Organic Compounds Lipids and lipid-like molecules Glycerolipids Triradylcglycerols Alkyldiacylglycerols

Introduction to DMG-PEG 2000 (CAS No. 160743-62-4)

DMG-PEG 2000, with the Chemical Abstracts Service (CAS) number 160743-62-4, is a versatile polymer widely used in various biomedical and pharmaceutical applications. This compound, also known as dimethylglycerol polyethylene glycol, is a linear polyethylene glycol (PEG) derivative that has gained significant attention due to its unique properties and potential in drug delivery systems, bioconjugation, and other advanced therapeutic applications.

The structure of DMG-PEG 2000 consists of a dimethylglycerol (DMG) head group attached to a PEG chain with a molecular weight of approximately 2000 Da. The DMG moiety provides additional functionality and stability, while the PEG chain imparts water solubility, biocompatibility, and reduced immunogenicity. These properties make DMG-PEG 2000 an ideal candidate for enhancing the pharmacokinetic and pharmacodynamic profiles of various drugs and biomolecules.

In recent years, significant advancements have been made in the use of DMG-PEG 2000 for improving drug delivery systems. One of the key areas of research is the development of PEGylated nanoparticles for targeted drug delivery. PEGylation, the process of attaching PEG chains to a drug or carrier molecule, has been shown to enhance the circulation time of drugs in the bloodstream by reducing renal clearance and increasing stability. This is particularly important for drugs with short half-lives or those that are rapidly metabolized by the body.

A study published in the Journal of Controlled Release demonstrated that DMG-PEG 2000-modified nanoparticles significantly improved the therapeutic efficacy of anticancer drugs by enhancing their accumulation in tumor tissues. The researchers found that the PEGylated nanoparticles exhibited prolonged circulation times and enhanced tumor targeting, leading to higher drug concentrations at the site of action and reduced systemic toxicity.

Beyond cancer therapy, DMG-PEG 2000 has also shown promise in other therapeutic areas. For instance, it has been used to improve the delivery of siRNA (small interfering RNA) for gene silencing applications. siRNA is a powerful tool for downregulating gene expression but faces challenges such as poor stability and inefficient cellular uptake. By conjugating siRNA with DMG-PEG 2000, researchers have been able to overcome these limitations and achieve more effective gene silencing in vivo.

In addition to its role in drug delivery, DMG-PEG 2000 has been explored for its potential in tissue engineering and regenerative medicine. The biocompatibility and hydrophilic nature of PEG make it an attractive material for fabricating scaffolds and hydrogels that can support cell growth and tissue regeneration. A recent study published in Biomaterials Science reported that DMG-PEG 2000-based hydrogels promoted the proliferation and differentiation of mesenchymal stem cells, suggesting its potential use in bone tissue engineering.

The versatility of DMG-PEG 2000 extends to its use as a stabilizer in protein formulations. Proteins are often sensitive to environmental factors such as temperature, pH, and mechanical stress, which can lead to aggregation and loss of activity. By incorporating DMG-PEG 2000 into protein formulations, researchers have observed improved stability and shelf life, making it a valuable additive in biopharmaceutical manufacturing.

In conclusion, DMG-PEG 2000 (CAS No. 160743-62-4) is a highly versatile polymer with a wide range of applications in biomedical and pharmaceutical research. Its unique combination of properties makes it an excellent candidate for enhancing drug delivery systems, improving gene therapy outcomes, supporting tissue engineering efforts, and stabilizing protein formulations. As research continues to advance, it is likely that new applications for this compound will be discovered, further solidifying its importance in the field.

• 2098070-20-1(2-(3-(Pyridin-3-yl)-1H-pyrazol-1-yl)acetimidamide)
• 2680771-01-9(4-cyclopentyl-3-{(prop-2-en-1-yloxy)carbonylamino}butanoic acid)
• 1444113-98-7(N-(3-cyanothiolan-3-yl)-2-[(2,2,2-trifluoroethyl)sulfanyl]pyridine-4-carboxamide)
• 332062-08-5(Fmoc-S-3-amino-4,4-diphenyl-butyric acid)
• 1270529-38-8(1,2,3,4,5,6-Hexahydro-[2,3]bipyridinyl-6-ol)
• 941977-17-9(N'-(3-chloro-2-methylphenyl)-N-2-(dimethylamino)-2-(naphthalen-1-yl)ethylethanediamide)
• 2138166-62-6(2,2-Difluoro-3-[methyl(2-methylbutyl)amino]propanoic acid)
• 89640-58-4(2-Iodo-4-nitrophenylhydrazine)
• 1449132-38-0(3-Fluoro-5-(2-fluoro-5-methylbenzylcarbamoyl)benzeneboronic acid)
• 2034271-14-0(2-(1H-indol-3-yl)-N-{[6-(thiophen-2-yl)-[1,2,4]triazolo[4,3-b]pyridazin-3-yl]methyl}acetamide)